• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Psychedelic Groundbreakers: Integration Communications

Microdose by Microdose
September 30, 2021
in Psychedelic Groundbreakers
Reading Time: 3 mins read
A A
Psychedelic Groundbreakers: Integration Communications

This week’s Psychedelic Groundbreaker is Integration Communications.

What’s this article series about? Psychedelic Groundbreakers is a get-to-know-you-style blog series highlighting prominent and groundbreaking companies in the psychedelics industry.

What’s your company vision?

Integration Communications envisions a world where psychedelics are safely, sustainably, effectively, and ethically integrated into our culture as tools for health, creativity, and human well-being.

Why was your company started?

The current revolution in wellness and mental health is positioning psychedelics to be the first new approach to Western healthcare in decades. They’re bringing with them an entire new psychedelic industry. Integration Communications was founded in 2020 to help new companies entering the psychedelic space, and established brands wanting to keep up with shifts in public culture, communicate their message while remaining in alignment with ethical values.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

What’s been the biggest challenge so far?

The biggest challenge has been keeping track of all the developments across the science, business, policy, and technology sector that are supporting the emergence of psychedelics into mainstream medicine. It seems like every day a new celebrity, media outlet, or TV series is talking about psychedelics, and the culture is changing faster than the research results are coming out—so maintaining sure that clear, honest science education gets through the noise takes a lot of effort—and repetition!

Continue on your trip...

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Psychedelic Groundbreakers: Integration Communications

What excites you most?

What’s most exciting for me is getting to work directly with all kinds of visionary, motivated founders and CEOs who are dedicating themselves to integrating psychedelics into our society. These folks are bringing a huge amount of experience and new perspective into the psychedelic industry, and they’re transforming it as they go. It’s a pleasure and delight to get to learn from and work with my clients.

What is your biggest lesson learned when raising capital?

Buy Lasix with Fast Shipping

What I’ve discovered in working with all kinds of clients who are raising capital (tech start-ups, non-profits, academic and training institutions, retreat centers) is that right now is probably the easiest time they’ll ever have raising funds for psychedelic products and services.

Did you notice any type of investor differences while raising money?

There’s something special about raising funds in the psychedelic space—in this space, more than perhaps any other space, funders and donors are most motivated by those projects that are most genuinely dedicated to community, sustainability, diversity, and giving back. Psychedelics, used in the right ways, have a tendency to encourage those values—and this investor field reflects that.

Describe your business model in 10 words or less

Helping purpose-driven companies of all kinds expand their audience and enhance their brand with clarity, efficiency, and accountability as they work to bring psychedelics into our society.

What tips would you give founders entering fundraising?

Define your values clearly, and make sure that they translate into your messaging. Also, make alliances with established partners early and often. Psychedelics and community go hand in hand.

 

We’d like to thank Integration Communications for being a part of the Psychedelic Groundbreaker series. Stay tuned for more profiles on leaders in the psychedelic industry, and click here to learn more about Integration Communications.

Would you like to participate in this series? Fill out this form and we’ll follow up with a review of your application.

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: Integration Communications
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
Psychedelic Titans with Boaz Wachtel of Ibogacine

Psychedelic Titans with Boaz Wachtel of Ibogacine

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.